BREAKING: AI Revolutionizes Prostate Cancer Treatment!
In a major breakthrough, an artificial intelligence (AI) platform has been granted approval by the American Medical Association (AMA) to develop treatment plans for prostate cancer patients. Avenda Health’s Unfold AI tool has received a category III Current Procedural Terminology (CPT) code, marking a significant step forward in cancer diagnosis and treatment.
The Unfold AI tool utilizes patient-specific data from prostate imaging and biopsies to generate a cancer probability map. This innovative technology provides a non-invasive prostate cancer estimation map derived from image-guided fusion biopsy and pathology. With this approval, Avenda Health cements its position as a leader in revolutionizing cancer care and making cutting-edge solutions accessible to all patients.
Category III codes are temporary designations that allow for the reporting and evaluation of emerging and experimental services and procedures. The data collected from the use of the Unfold AI tool will provide valuable insights to the medical community.
Avenda Health is currently involved in an interventional clinical trial focused on prostate cancer. As part of the trial, they are testing the Unfold AI tool alongside their FocalPoint System, which is still awaiting approval. This collaboration shows the company’s dedication to advancing the treatment options available to prostate cancer patients.
The North American market for prostate cancer is projected to reach $12.6 billion by 2027, highlighting the urgent need for effective treatment solutions. In 2023 alone, there have been an estimated 288,300 new cases and approximately 34,700 deaths caused by prostate cancer, according to the American Cancer Society.
Avenda Health has also partnered with Urology Associates to conduct trials of the Unfold AI device. Their plans include expanding these trials to teaching hospitals across the United States, furthering their mission to transform cancer care.
In another exciting development, Spanish software provider Quilbim and Phillips have joined forces to launch an AI-based device focused on prostate cancer detection. This device utilizes advanced imaging and reporting solutions to detect prostate cancer, providing even more hope for patients in the fight against this disease.
With the approval of the Unfold AI tool, the future of prostate cancer treatment looks promising. Patients can now benefit from more accurate diagnoses and personalized treatment plans, leading to improved outcomes. The medical community is eager to see the results of this groundbreaking technology.
What do you think about the use of AI in cancer treatment? Do you believe it will significantly improve patient outcomes? Share your thoughts and join the discussion below!
IntelliPrompt curated this article: Read the full story at the original source by clicking here